Mofegiline
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (2E)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Non-regulated |
| Routes | Oral[1] |
| Pharmacokinetic data | |
| Half-life | 1-3 hours[1] |
| Excretion | Urine[2] |
| Identifiers | |
| CAS number | 119386-96-8 |
| ATC code | None |
| PubChem | CID 6437850 |
| ChemSpider | 4942371 |
| UNII | 1FMJ6D8Y1B |
| Synonyms | MDL-72,974A |
| Chemical data | |
| Formula | C11H13F2N |
| Mol. mass | 197.224 g/mol |
| SMILES | eMolecules & PubChem |
|
Mofegiline (MDL-72,974) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) and semicarbazide-sensitive amine oxidase (SSAO) which was under investigation for the treatment of Parkinson's disease and Alzheimer's disease,[3][4][5][6] but was never marketed.[7]
[edit] See also
[edit] References
- ^ a b Stoltz M, Reynolds D, Elkins L, Salazar D, Weir S (September 1995). "Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial". Clinical Pharmacology and Therapeutics 58 (3): 342–53. doi:10.1016/0009-9236(95)90252-X. PMID 7554709.
- ^ Dulery BD, Schoun J, Zreika M, et al. (March 1993). "Pharmacokinetics of and monoamine oxidase B inhibition by (E)-4-fluoro-beta-fluoromethylene benzene butanamine in man". Arzneimittel-Forschung 43 (3): 297–302. PMID 8489556.
- ^ Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A (1988). "Design and early clinical evaluation of selective inhibitors of monoamine oxidase". Progress in Neuro-psychopharmacology & Biological Psychiatry 12 (6): 967–87. PMID 3266532.
- ^ Zreika M, Fozard JR, Dudley MW, Bey P, McDonald IA, Palfreyman MG (1989). "MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease". Journal of Neural Transmission. Parkinson's Disease and Dementia Section 1 (4): 243–54. PMID 2597310.
- ^ Palfreyman MG, McDonald IA, Bey P, Danzin C, Zreika M, Cremer G (1994). "Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential". Journal of Neural Transmission. Supplementum 41: 407–14. PMID 7931257.
- ^ Thiffault C, Quirion R, Poirier J (March 1998). "Effect of the MAO-B inhibitor, MDL72974, on superoxide dismutase activity and lipid peroxidation levels in the mouse brain". Synapse (New York, N.Y.) 28 (3): 208–11. doi:10.1002/(SICI)1098-2396(199803)28:3<208::AID-SYN3>3.0.CO;2-E. PMID 9488505.
- ^ Ganellin, C. R.; Triggle, D. J.; Macdonald, F. (1997). Dictionary of pharmacological agents. CRC Press. p. 1370. ISBN 978-0-412-46630-4. http://books.google.com/books?id=A0THacd46ZsC&pg=PA1370. Retrieved 25 November 2011.
|
|
|
|
